Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
Zacks Small Cap Research on MSN21h
LGND: First Steps into Cell & Gene TherapyLGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational ...
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback